Denali Therapeutics Inc.

4DN.F·Frankfurt·Healthcare
Compare
18.41+1.00 (+5.74%)today
As of Nov 5, 8:18 AM CET · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close17.41
Open18.41
Day range—
52-week range12.4223.47
Off day high0.00%
Off 52-week high−21.56%
Volume10.00
Avg. volume (3M)19.00
Market cap2.94B
EPS (TTM)-1.41
Forward P/E-8.11
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)1.08
Shares outstanding159.85M
Short interest—
Earnings dateNov 3, 2026
Analyst target—
Profit margin0.00%

Against its peers

Compare in full ›
4DN.F B9A.F IONS SRPT MAZE ALEC
Market cap 2.94B 2.45B 6.67B 2.01B 1.85B 254.58M
P/E (TTM) — 250.7 — — — —
Forward P/E -8.1 — -35.0 7.8 -10.5 -3.1
Price/book 3.2 1.2 15.1 1.3 4.1 -25.6
Dividend yield — 0.68% — — — —
1-year change +28.62% +5.23% −45.88% −0.70% +6.54% +63.35%
Today +5.74% −0.29% −0.67% +2.43% +3.50% +11.22%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Related companies

Compare ›

The businesses closest to Denali Therapeutics's by what they do, from their descriptions, with the same industry weighted in.

Company Mkt cap Price Today
BioArctic AB (publ)B9A.F · Biotechnology 2.45B 27.58 −0.29%
Ionis Pharmaceuticals, Inc.IONS · Biotechnology 6.67B 40.15 −0.67%
Sarepta Therapeutics, Inc.SRPT · Biotechnology 2.01B 18.99 +2.43%
Maze Therapeutics, Inc.MAZE · Biotechnology 1.85B 33.38 +3.50%
Alector, Inc.ALEC · Biotechnology 254.58M 2.2800 +11.22%
PTC Therapeutics, Inc.PTCT · Biotechnology 5.76B 68.97 +1.25%
Korsana Biosciences, Inc.KRSA · Biotechnology 1.39B 30.56 −4.38%
IDEAYA Biosciences, Inc.IDYA · Biotechnology 3.12B 32.36 +3.29%

The stocks whose daily moves over the past year went most closely with Denali Therapeutics's: the correlation of their daily returns, where 1 would be moving as one.

Company Mkt cap Price Today
Denali Therapeutics Inc.4DN.MU · Correlation 0.67 2.79B 17.43 +2.53%
Ultragenyx Pharmaceutical Inc.UP0.F · Correlation 0.37 1.49B 15.11 +8.86%
Intellia Therapeutics, Inc.38I.F · Correlation 0.33 1.51B 10.76 +0.37%
Acadia Pharmaceuticals Inc.DR6.F · Correlation 0.31 3.26B 18.94 +2.85%

What visitors to Denali Therapeutics's page also look at.

Company Mkt cap Price Today
Denali Therapeutics Inc.4DN.MU 2.79B 17.43 +2.53%
Ultragenyx Pharmaceutical Inc.RUP0.F 1.49B 15.11 +8.86%
Intellia Therapeutics Inc.38I.F 1.51B 10.76 +0.37%
Innovent Biologics Inc.6IB.F 17.27B 9.91 +3.42%
ACADIA PHARMACEUTICALS INC.DR6.F 3.26B 18.94 +2.85%

From the 4SEARCH.business instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 20 min.

Latest news

All 4DN.F news ›
Seeking Alpha··3 outletsPositive

Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript

Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Laura HansenRyan Watts - Co-Founder, President, CEO & DirectorKatie Peng - Chief Commercial OfficerPeter Chin - Acting Chief Medical Officer & Head of…

REGNNVDASPCXGS
More from 2 other outlets
MarketScreener··2 outletsPositive

B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating

Denali Therapeutics has an average rating of buy and mean price target of $34.88, according to analysts polled by FactSet. ... Biotechnology & Medical Research B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains…

DNLIDXCM
More from 1 other outlet
markets.businessinsider.com·Positive

Denali Therapeutics (DNLI) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Jessica Fye maintained a Buy rating on Denali Therapeutics today and set a price target of $29.00. According to TipRanks, Fye is a 5-star analyst with an average return of 9.6% and a 55.50% success rate. Fye covers the…

DNLIARWR
markets.businessinsider.com·Positive

Stifel Nicolaus Remains a Buy on Denali Therapeutics (DNLI)

In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on Denali Therapeutics, with a price target of $41.00. Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA…

DNLIURGNSNY

From the 4Search news index, newest first.

In the news

19mentions in 30 days
19with it in the headline
Positivesentiment

Mentioned with

Wedbush9Biogen8Biotechnology & Medical Research Wedbush7Denali Therapeutics Inc.7Dexcom, Inc7Biotechnology & Medical Research Rbc6Morgan Stanley6Medical Equipment5

People in the coverage

Denali16Sarita Garza15Ryan Watts14William Blair11Stifel10Avlayah9

Themes

Healthcare11Finanzen9Dnli8Consensus5EPS5Ratings5Biib4Boost Price Target4

Most coverage from

  1. marketscreener.com8
  2. markets.businessinsider.com6
  3. seekingalpha.com2
  4. themarketsdaily.com2
  5. pluang.com1

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance